NCT05725343 (CANAL) is a Phase 3 clinical trial of Canakinumab in Lung Cancer, sponsored by Mario Negri Institute for Pharmacological Research.

Who is sponsoring NCT05725343?

NCT05725343 is sponsored by Mario Negri Institute for Pharmacological Research.

What drugs are being tested in NCT05725343?

Interventions in NCT05725343: Canakinumab, Placebo.

What condition does NCT05725343 study?

NCT05725343 studies Lung Cancer.

Is NCT05725343 still recruiting?

NCT05725343 is currently terminated. Last updated 13 February 2023.

Last reviewed 2023-02-13 · How we verify

NCT05725343: CANAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer

Terminated Phase 3 Last updated 13 February 2023

What this trial tests

Phase 3 trial testing Canakinumab in Lung Cancer in 350 participants. Terminated before completion.

Timeline

3 February 2022

Primary endpoint
3 April 2022

21 September 2022

Quick facts

Lead sponsor	Mario Negri Institute for Pharmacological Research
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	350
Start date	3 February 2022
Primary completion	3 April 2022
Estimated completion	21 September 2022
Sites	6 locations across Italy

Drugs / interventions tested

Canakinumab (CANAKINUMAB) — full drug profile →
Placebo

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Mario Negri Institute for Pharmacological Research

Who can join

Adults 18 to 75, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized phase III, double-blind, placebo-controlled, multicenter clinical trial.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment.
Li M, Jiang P, Yang Y, Xiong L, et al · · 2023 · cited 28× · PMID 38066523 · DOI 10.1186/s40164-023-00464-5
Targeting neutrophils for cancer therapy.
Kwak JW, Houghton AM. · · 2025 · cited 11× · PMID 40374764 · DOI 10.1038/s41573-025-01210-8
The promise of IL-1β modulation in NSCLC clinical context.
Ghiringhelli F, Rébé C. · · 2026 · PMID 41694383 · DOI 10.3389/fimmu.2026.1773253

Verify or expand the search:

Other trials of Canakinumab

Trials testing the same drug.

NCT06038526 — Evaluation of Canakinumab in High-Risk Former-Smokers · Phase 2 · active not recruiting
NCT05984602 — A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclit · Phase 1 · active not recruiting
NCT05401578 — Canakinumab for the Treatment of Postprandial Hypoglycemia · Phase 3 · recruiting
NCT05641831 — Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPA · Phase 2 · recruiting
NCT05535738 — Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation · Phase 2, PHASE3 · recruiting

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Mario Negri Institute for Pharmacological Research trials

Trials by the same sponsor.

NCT07428018 — Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Onco · Phase 2 · not yet recruiting
NCT07331103 — RESOLving INflammation Through Diet for Health (RESOLVIN) · NA · recruiting
NCT06994468 — Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy · NA · completed
NCT07111624 — A New Crowding Indicator in the Emergency Department · not yet recruiting
NCT07021118 — Mild TBI in the Emergency Department · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05725343 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mario Negri Institute for Pharmacological Research
Last refreshed: 13 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05725343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing